Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (clinicaltrials.gov) - Jun 17, 2026 - P2 | N=40 | Recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Trial primary completion date: Dec 2026 ➔ Dec 2027
Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CTLA4
|